MitoRx Therapeutics LtdMitoRx Therapeutics Ltd has raised £5.5m in a seed financing to advance Myo‑004, a small molecule mitochondrial-targeted obesity therapy enabling fat loss while preserving lean muscle mass.
Sofinnova PartnersSofinnova Partners has closed its new investment fund, Capital XI, at €650m, far exceeding its original target. The early-stage biotech and medtech-focused fund will invest mostly in Series A, but also seed financings of companies, including oncology, inflammation and immunology, CNS, and cardio-metabolic diseases.
Medicxi VC specialist Medicxi has closed its oversubscribed €500m Fund V to support existing biopharmaceutical developers, and creating new companies across all development stages.
chokniti - Adobe StockSwiss biotech Virometix has raised US$15m in fresh funding to accelerate development of its lead pneumococcal vaccine candidate and advance its next-generation synthetic vaccine platform.
Scripta TherapeuticsOxford-based techbio startup Scripta Therapeutics has emerged from stealth with a biology-first platform targeting the master regulators of disease.
adobe stock photos - JustlightAstraZeneca’s baxdrostat cuts 24-hour systolic BP by 14mmHg in resistant hypertension, offering a novel mechanism and major market potential.
stock.adobe.photos.com - gaviAstraZeneca plc acquires SixPeaks Bio Inc to target muscle‑preserving obesity therapies, boosting its pipeline in a US$30 bn fast-growing weight-loss market.
adobe stock photos - AkuAku A landmark discovery by a team of South Korean scientists could transform the way RNA-based vaccines and therapeutics are developed and produced. Researchers led jointly by Professor V. Narry Kim and Professor Jin-Hong Kim have identified a series of viral RNA motifs that make conventional messenger RNA (mRNA) far more stable and efficient, potentially revolutionising RNA drug manufacturing.
Adobe stock photos - Dzmitry Semaglutide (Ozempic®) and Tirzepatide (Mounjaro®) not only promote weight loss but also significantly reduce the risk of major cardiovascular events in patients with type 2 diabetes. Real-world evidence from the Technical University of Munich and Harvard Medical School shows up to 18% lower risk of heart attack and stroke, highlighting the growing potential of GLP-1 therapies in cardiometabolic care.
Adobe stock photos - Matthew Eli Lilly and Novo Nordisk cut US obesity drug prices under Trump’s MFN plan, offering Zepbound, Wegovy and others via Medicare, Medicaid and LillyDirect.